Future research into non-Hodgkin lymphoma treatments needs to explore long-term outcomes and a better understanding biologic ...

Five diagnosed prevalent cases will grow to over 714,000. Diagnosed incident cases of B-cell non-Hodgkin’s lymphoma (B-cell NHL) across the seven major markets (7MM) are expected to increase from 200, ...

A lymph node biopsy is the main method of diagnosing both non-Hodgkin’s and Hodgkin’s lymphoma, including diffuse large B-cell lymphoma, which is the most common form of non-Hodgkin’s lymphoma.

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma.

Non-Hodgkin ... cells in the lymphatic system. They are generally classified according to the cancer's growth rate as high grade (fast growing) or low grade (slow growing). Diffuse large B-cell ...

Epcoritimab is a treatment for diffuse large B-cell lymphoma, a form of Non-Hodgkin lymphoma affecting 2000 Australians annually and characterised by its aggressive growth. Set to be subsidised by ...

LIKE most of us, when Zee Valentina began feeling more tired than normal, she – and even her doctors – dismissed it as ...